ARCHBOW CONSULTING NEWS

How Pharmaceutical Companies Deliver Successful Patient Access Launch Strategies for Biosimilars

Optimizing Cross-Functional Collaboration for Compliance and Access

Have you done your research?

How to Drive Specialty and Orphan Drug Launch Success with a Patient-Centric Approach

6 Considerations When Launching a 3PL Program

Omnicom Health Group Acquires Archbow Consulting

Understanding Pharmaceutical Market Access Differences in the US and Europe

The Smart Way to Approach Pharmaceutical Reimbursement HUB Innovation

How Cell and Gene Therapy Companies Can Adapt in an Evolving Commercial Landscape

2021 Health System Specialty Pharmacy Trend Report

How Healthy are Your Pharmaceutical Patient Access Programs?

6 Ways Pharmaceutical Companies Can Adapt to Improve the Chances of Project Success

The Five Data Sets Every Specialty Pharmaceutical Needs Today

Leveraging Hospital Market Research to Impact Future Adoption of Cell and Gene Therapies

Which pharmaceutical HUB design is right for you? Insource vs. Outsource vs. Hybrid.

Track-and-Trace 101

What to know before you migrate a Patient Service Program

Archbow expands cell and gene therapy expertise with newest team member: Paul Furgal

Going global with innovative pharmaceutical contracting and pricing

Why “Demand Chain” is the new “Supply Chain” in Cell and Gene Therapy